Spotlights

Avanza

Euroclear AUXESIS PHARMA HOLDING AB (publ) has now entered into an agreement with the issuance institute Avanza Sweden. All shareholders will be registered with Euroclear

Read More »

Scenario valuation 2023

Valuation AUXESIS 03/2023 Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is

Read More »

Investor Forum

Investor Invitation We are excited to invite you to our first Investor Forum monday the 30th of january at the Karolinska Institute, Huddinge, Sweden. On

Read More »

Euroclear

News Euroclear Sweden AUXESIS PHARMA HOLDING AB (publ) register of shareholders is in process of being digitalised and transferred to the Euroclear system. As a client

Read More »

Memorandum

Update There is exciting news in Auxesis Pharma. Trademarks, new areas of application, clinical studies and trials, production facilities, to name a few. Complete pdf

Read More »

Share Issue Offering

Do you want to join the journey? AUXESIS PHARMA HOLDING AB (publ) is increasing its stock with maximum 600.000 shares at a price of SEK 30/share.Duration for purchasing shares is from 10th

Read More »

Public Limited Company

AUXESIS PHARMA HOLDING AB (publ) is now registered with the Swedish Companies Registration Office as a Public Limited Company (PLC) with a share capital of SEK 500,000. A

Read More »

Scenario valuation

Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is now available. One-Pager

Read More »

New Board Members

Welcome as Board Members – Charlotta Larsson and Rune Nordström. Thank you to all shareholders for a great meeting and big thanks to Lars Larsson

Read More »